Cognition Therapeutics, Inc. — Q3 2023 Form 10-Q
Business context and reporting period. Clinical-stage biopharmaceutical company developing therapies for age-related CNS and retinal diseases. This unaudited report covers the three and nine months ended September 30, 2023; comparisons are with the corresponding 2022 periods. CT1812 is its lead candidate. The company had no product sales revenue.
Financial performance and position
- Q3 2023: Operating expenses were $14.7 million, including $11.7 million of R&D and $3.1 million of G&A. Grant income of $7.7 million and other income of $0.3 million partly offset expenses; net loss was $6.7 million, or $0.22 per share. Q3 2022 net loss was $6.6 million, or $0.29 per share.
- First nine months: Operating expenses were $35.5 million versus $34.3 million in 2022. Grant income was $18.0 million versus $18.2 million. Net loss increased to $17.6 million from $16.2 million; loss per share improved to $0.59 from $0.71, reflecting a higher weighted-average share count.
- Cash flow: Operating activities used $10.6 million in the first nine months, versus $8.3 million in 2022. Investing activities used $0.1 million; financing activities provided $2.1 million, mainly from ATM and Lincoln Park share sales. Cash declined $8.6 million to $33.0 million.
- Liquidity and obligations: Current assets were $36.0 million and current liabilities $8.2 million at September 30. Total liabilities were $9.8 million, principally accounts payable, accruals, grant deferrals, and lease liabilities; the filing reports no outstanding principal on the insurance-premium financing loan at quarter-end. Operating lease liabilities were $0.7 million.
- Other metrics: Total assets were $38.8 million and stockholders’ equity $28.9 million. Accumulated deficit was $133.0 million. No meaningful product gross margin is reported because there are no product sales; grant income is reported as other income, not revenue.
Material changes versus prior comparable periods
- Q3 R&D expense increased $3.4 million year over year, driven by greater Phase II trial activity, clinical-supply manufacturing, and preclinical spending. G&A fell $1.3 million, mainly due to lower professional fees and insurance costs.
- For the nine-month period, R&D rose $1.7 million, reflecting higher personnel and preclinical costs, partly offset by lower clinical-program and manufacturing costs. G&A declined $0.4 million.
- Nine-month operating cash use increased by $2.2 million year over year. Cash and cash equivalents fell from $41.6 million at December 31, 2022 to $33.0 million at September 30, 2023.
- Common shares outstanding rose from 29.0 million at year-end 2022 to 30.4 million at September 30, 2023, including issuance through the ATM and equity-line financing.
Outlook, commentary, and risks
- Management estimated existing cash and non-dilutive grant income would fund operating and capital needs through November 2024, assuming no use of remaining ATM or Lincoln Park capacity. The company also states additional funding will be needed beyond this period.
- At September 30, approximately $37.5 million remained available under the $40 million ATM program and $34.8 million under the $35 million Lincoln Park equity line. These are potential financing sources, not committed cash proceeds, and share issuance could dilute existing holders.
- Management expects significant expenses and losses to continue. Future funding needs depend on trial progress and costs, grant availability, manufacturing, regulatory work, and other factors. No formal revenue or profitability guidance was provided.
- The filing cites SNAP findings that a single oral CT1812 dose rapidly displaced amyloid-beta oligomers from synapses in people with Alzheimer’s disease, and SEQUEL top-line findings of improved synapse activity and brain-region connectivity after four weeks. These are clinical findings, not evidence of regulatory approval or commercial success.
- Some trial participants had asymptomatic, reversible elevations in serum liver chemistries; the company harmonized and, where appropriate, increased monitoring across trials.
- Key risks include clinical and regulatory uncertainty, reliance on CT1812, dependence on grants and future financing, possible dilution, third-party manufacturing and trial execution, competition, and the possibility that cash needs exceed estimates. Management reported no material change to previously disclosed risk factors, no material litigation contingency, and effective disclosure controls and internal controls over financial reporting.
Important facts for investors to verify
- Whether the November 2024 cash-runway estimate remains achievable, given operating cash use, trial spending, and its assumption of no ATM or Lincoln Park usage.
- Clinical-trial progress and full results for CT1812, including the significance and durability of SNAP and SEQUEL findings and the handling of liver-chemistry elevations.
- Timing, terms, and potential dilution from any future ATM or Lincoln Park share sales, and availability of additional grants or other financing.
- How much of reported grant income is collectible and eligible under award terms; grants are subject to allowable-cost requirements and government audits.